Skip to headerSkip to main contentSkip to footer
Get our Free E-newslettersGet our Free E-newsletters
Kiplinger logoLink to homepage
Get our Free E-newslettersGet our Free E-newsletters
Subscribe to Kiplinger
Subscribe to Kiplinger
Save up to 76%
Subscribe
Subscribe to Kiplinger
  • Store
  • Home
  • Investing
  • Retirement
  • Taxes
  • Personal Finance
  • Your Business
  • Wealth Creation
  • More
    • Podcasts
    • Economic Outlooks
    • Tools
  • My Kiplinger
    • Kiplinger's Personal Finance Magazine
    • The Kiplinger Letter
    • The Kiplinger Tax Letter
    • Kiplinger's Investing for Income
    • Kiplinger's Retirement Report
    • Store
    • Manage My E-Newsletters
    • My Subscriptions
  • Home
  • investing
  • stocks
  • growth stocks
growth stocks

10 Small-Cap Growth Stocks to Buy Now

In a year when the major market indexes are struggling to put up gains, it might be time to take a closer look at smaller stocks with outsized growth prospects.

by: Dan Burrows
April 26, 2018

Getty Images

In a year when the major market indexes are struggling to put up gains, it might be time to take a closer look at smaller stocks with outsized growth prospects. Historically, small-cap growth stocks have a low performance correlation to stocks with large market values, asset manager Federated Investors notes. They also tend to outperform stocks with big market caps over time, too.

Small-cap growth stocks have certainly paid off so far in 2018. The large-cap Dow Jones Industrial Average is off 3% for the year-to-date. But the small-cap growth benchmark Russell 2000 growth index is actually flat.

“What we love about small-cap growth stocks is that they are small businesses that constantly innovate and are creating their own demand,” writes Federated Kaufmann Fund (KAUAX) portfolio manager Stephen DeNichilo. “They are not reliant on market tailwinds. They create their own trajectory and are masters of their own universe.”

When we talk about small-cap growth stocks, we generally mean stocks with market values of between about $300 million and $3 billion. As for the growth part, the companies these stocks represent might be generating annualized sales gains of 30% or more. Naturally, expectations for outsized earnings growth are part of the equation too.

Here are 10 small-cap growth stocks to buy now. These 10 picks are smaller companies that have average analyst ratings of “Buy” or better. Several of these small-cap growth stocks that stood out are health-care names, but specialty chemicals, information technology and even veterinary services make appearances too. One thing they all have in common is that analysts are bullish on them at current levels.

  • 30 Blue-Chip Stocks With the Best Analyst Ratings
Data is as of April 25, 2018. Companies are listed in alphabetical order. Analysts’ ratings provided by Zacks Investment Research. Click on ticker-symbol links in each slide for current share prices and more.

1 of 10

Aimmune Therapeutics

Black lunchbox with skull and crossbones on lid and peanuts overflowing out of container

Getty Images

  • Market value: $1.8 billion
  • Analysts’ opinion: 7 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell
  • Aimmune Therapeutics (AIMT, $30.82) aims to save lives. The clinical-stage biopharmaceutical company is developing treatments to desensitize people with food allergies. If successful, its AR101 treatment would ensure that accidental exposure to say, peanuts, wouldn’t cause a life-threatening condition.

Analysts at Credit Suisse, who rate shares at “Outperform” (equivalent of buy), say the late-stage clinical data looks encouraging. If all goes well, Aimmune could get U.S. Food and Drug Administration approval next year and have a blockbuster on its hands. Credit Suisse’s best-case scenario has Aimmune capturing up to 70% of the market for such drugs in the U.S. and Europe.

 

  • 10 Blockbuster Drugs of the Future

2 of 10

Esperion Therapeutics

red flags for high risk cholesterol- a detail of blood laboratory screening results with focus on lipids panel

Getty Images

  • Market value: $1.9 billion
  • Analysts’ opinion: 7 strong buy, 0 buy, 4 hold, 0 sell, 0 strong sell
  • Esperion Therapeutics (ESPR, $69.25) is developing a cholesterol-lowering drug for patients who don’t tolerate current crop of medications on the market, and analysts think it has a winner on its hands. At Stifel, which rates shares at “Buy,” analysts expect the company to complete regulatory submissions for approval by the first quarter of next year. Ultimately, Stifel thinks Esperion’s cholesterol drug – currently known as ETC-1002, can eventually generate more than $2 billion in sales in the U.S. alone.

The company, which is forecast to book revenue of just $32 million this year, according to data from Thomson Reuters, is poised for breakout growth if ETC-1002 hits like Stifel thinks it will.

 

  • The 15 All-Time Best-Selling Prescription Drugs

3 of 10

Evolent Health

medical techonlogy concept,smart doctor hand working with modern laptop computer in modern office with virtual icon diagram

Getty Images

  • Market value: $1.3 billion
  • Analysts’ opinion: 12 strong buy, 0 buy, 0 hold, 0 sell, 0 strong sell

Analysts are bullish on Evolent Health’s (EVH, $16.55) ability to deliver outsized revenue growth. Indeed, Wall Street expects the health-care software and consulting services company to deliver a year-over-year sales increase of 32% in 2018.

William Blair analysts say that “at a minimum,” shares will appreciate in line with strong sales growth going forward. Health-care providers such as Orlando Health, Community Care Cooperative and Crystal Run Healthcare are just some of the company’s clients driving these gains, Blair notes. “We thus reiterate our ‘Outperform’ rating and continue to recommend purchase of EVH shares,” the analysts say.

Analysts project long-term earnings growth to average 30% annually for the next five years.

 

  • The 50 Best Stocks of All Time

4 of 10

Glaukos

Diagnosis list with Glaucoma and glasses. Eye disorder concept.

Getty Images

  • Market value: $1.1 billion
  • Analysts’ opinion: 8 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell
  • Glaukos (GKOS, $31.52) makes the iStent, a tiny medical implant used to reduce eye pressure caused by glaucoma. The device, which is implanted during cataract surgery, currently is in use in 300,000 eyes around the world.

Analysts expect the company to deliver average annual profit growth of 40% for the next half-decade. That’s in part because Glaukos has a first-mover advantage with iStent, and the market for such a product remains largely untapped.

Perhaps most important, however, is that Glaukos has other glaucoma products in the works. “(The) pipeline, if successful, would give Glaukos the broadest set of products to treat glaucoma of any pharmaceutical or device company,” write analysts at William Blair Equity Research, who rate shares at “Outperform.”

 

  • Dividend Aristocrats With 50+ Years of Payout Growth

5 of 10

Installed Building Products

A wall of pink insulation in a new construction

Getty Images

  • Market value: $1.8 billion
  • Analysts’ opinion: 5 strong buy, 1 buy, 2 hold, 0 sell, 0 strong sell
  • Installed Building Products (IBP, $31.52) has been on an acquisition tear. The maker of home and commercial garage doors and control systems bought its fourth company in as many months in early April. Last year IBP bought 16 companies – predominantly small chains that supply and install building products, Columbus Business First reports.

Analysts largely approve of the company’s growth-through-acquisition strategy given the robust national housing market. Credit Suisse rates shares in IBP at “Outperform,” citing a “favorable macroeconomic backdrop” and “positive industry fundamentals.”

Wall Street’s pros, on average, expect earnings per share to rise 40% this year to $2.86 a share, according to a survey by Thomson Reuters. Revenue is projected to increase nearly 16% to $1.31 billion.

 

  • The 10 Best Dividend Stocks of All Time

6 of 10

Mindbody

Getty Images

  • Market value: $1.9 billion
  • Analysts’ opinion: 10 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell
  • Mindbody (MB, $39.00) provides cloud-based business management software for the wellness services industry. Think gyms, spas and salons. Now, a recent acquisition adds thousands of fitness studios like yoga, Pilates and CrossFit into the fold.

Mindbody in March acquired Booker, a cloud-based booking management platform, for $150 million. Together, the integrated company will offer everything from marketing and retention tools to booking and payments processing for the health and wellness services industries.

Analysts think the merger will allow earnings per share to more than double in 2019, to 47 cents a share from a projected 22 cents a share this year, according to data from Thomson Reuters. Wall Street expects revenue to rise 29% this year and 24% in 2019.

 

7 of 10

PetIQ

Cropped shot of a vet trying to listen to a bulldog puppy's heartbeat

Getty Images

  • Market value: $535.6 million
  • Analysts’ opinion: 4 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell

Analysts think PetIQ’s (PETQ, $22.53) sales growth is the cat’s meow. The company, which makes branded treats and medications for cats and dogs, is expanding into veterinary services. It acquired VIP Petcare in January and plans to open 20 to 30 veterinary service clinics during 2018, including 20 in Walmart (WMT) locations, note analysts at William Blair Equity Research, who rate shares at “Outperform.”

Sales are forecasts to jump by almost 79% in 2018 alone, according to data from Thomson Reuters.

“Management continues to forecast that its veterinary services clinics – coupled with the company’s core pet medication product lines – will help PetIQ achieve total sales of more than $1 billion by 2023,” Blair analysts say. PetIQ recorded just $267 million in sales last year.

 

  • 10 Biggest Product Recalls of All Time

8 of 10

PQ Group

Close-up on yellow lines painted on fresh black tarmac.

Getty Images

  • Market value: $1.9 billion
  • Analysts’ opinion: 7 strong buy, 0 buy, 2 hold, 0 sell, 0 strong sell

Specialty chemical company PQ Group (PQG, $14.37) is set to deliver truly outsized annualized profit growth, the pros say. They expect earnings per share to increase an average of 35% annually for the next five years, according to data from Thomson Reuters.

Some of the bullishness hinges on the rapid adoption of ThermoDrop, a thermoplastic material used to paint lines on roads. Analysts at Credit Suisse rates shares at “Outperform,” citing demand for ThermoDrop, which is supposed to increase crews’ productivity by as much as 35%, and some other specialty products.

The analysts also are bullish on PQ Group’s progress in paying down debt and boosting free cash flow.

 

9 of 10

Quidel

3d render Bacteria blue closeup (depthof field)

Getty Images

  • Market value: $2.0 billion
  • Analysts’ opinion: 4 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell

Analysts are bullish on Quidel’s (QDEL, $54.86) growth prospects.

The maker of diagnostic healthcare tests was once pigeonholed as “a flu company and a stock to be traded around the respiratory season,” note William Blair analysts, who rate shares at “Outperform.” But FDA approvals to test for other viruses such as Lyme disease and the 2017 acquisition of Triage MeterPro cardiovascular and toxicology assets from Alere have the company set on a new path.

Analysts expect Quidel’s earnings to rise an average of 48% a year over the next five years, according to Thomson Reuters data.

“When looking at the formal longer-term forecast for the company, we believe the company is set up well for a number of years of revenue and earnings growth,” William Blair says.

 

  • The 10 Best Tech Stocks of All Time

10 of 10

Zogenix

Epileptic seizure

Getty Images

  • Market value: $1.4 billion
  • Analysts’ opinion: 5 strong buy, 0 buy, 0 hold, 0 sell, 0 strong sell
  • Zogenix (ZGNX, $39.15) is a small pharmaceutical company that targets orphan diseases, which the FDA defines as conditions that affect fewer than 200,000 people nationwide. Cystic fibrosis and Lou Gehrig’s disease are two of the better-known orphan diseases.

Zogenix is targeting Dravet syndrome, a type of epilepsy. Analysts say promising data from clinical trials of fenfluramine, also known as ZX008, in treating Dravet syndrome make the stock a buy. “We continue to remain bullish on Zogenix shares as ZX008 is poised to become the therapy-of-choice amongst epileptologists/neurologists,” Stifel analysts say.

The company’s earnings are projected to grow at an average annual rate of 25% for the next five years, according to data from Thomson Reuters.

 

  • stocks to buy
  • small cap stocks
  • Becoming an Investor
  • stocks
  • bonds
  • growth stocks
Share via EmailShare on FacebookShare on TwitterShare on LinkedIn

Recommended

13 Best Warren Buffett Growth Stocks
stocks

13 Best Warren Buffett Growth Stocks

Warren Buffett might be known as a legendary value investor, but don't ignore his growth holdings. Here, we examine 13 of "the Oracle's" best growth s…
September 22, 2020
Bonds: 10 Things You Need to Know
Investing for Income

Bonds: 10 Things You Need to Know

Bonds can be more complex than stocks, but it's not hard to become a knowledgeable fixed-income investor.
July 22, 2020
Stock Market Today 2/24/21: Dow Jones Cruises to Record Altitude
Stock Market Today

Stock Market Today 2/24/21: Dow Jones Cruises to Record Altitude

The Nasdaq spewed red ink to kick off Tuesday morning but recovered most of its ground, with Fed comments helping to soothe investor concerns.
February 24, 2021
2 Top-Tier T. Rowe Price Mutual Funds
mutual funds

2 Top-Tier T. Rowe Price Mutual Funds

T. Rowe Price's mutual funds typically stand out among their peers, but these two selections provide elite equity and bond exposure for this point in …
February 24, 2021

Most Popular

Where's My Stimulus Check? Use the IRS's "Get My Payment" Portal to Get an Answer
Coronavirus and Your Money

Where's My Stimulus Check? Use the IRS's "Get My Payment" Portal to Get an Answer

The IRS has an online tool that lets you track the status of your stimulus checks.
February 19, 2021
Want More Tax-Free Retirement Income? One Man’s Whole Life Decision
life insurance

Want More Tax-Free Retirement Income? One Man’s Whole Life Decision

Whole life insurance might not be something that’s on your retirement planning radar, but for this client, here’s how it served his need to control ta…
February 23, 2021
The Current Plan for $1,400 Checks
Coronavirus and Your Money

The Current Plan for $1,400 Checks

Here's what you need to know about the stimulus check plan currently being considered in Congress for President Biden's COVID-relief package.
February 18, 2021
  • Customer Service
  • About Us
  • Advertise With Us (PDF)
  • Privacy Policy
  • Cookie Policy
  • Kiplinger Careers
  • Accessibility
  • Privacy Preferences

Subscribe to Kiplinger's Personal Finance

Be a smarter, better informed investor.
Save up to 76%Subscribe to Kiplinger's Personal Finance
Dennis Publishing Ltd logoLink to Dennis Publishing Ltd website
Do Not Sell My Information

The Kiplinger Washington Editors, Inc., is part of the Dennis Publishing Ltd. Group.
All Contents © 2021, The Kiplinger Washington Editors

Follow us on InstagramFollow us on FacebookFollow us on TwitterConnect on LinkedInConnect on YouTube